Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 10pembrolizumab 7Cisplatin 7Oxaliplatin 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3fludarabine 2Specimen Handling 2Radiation 2Ipilimumab 2Drug Therapy 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trametinib 1tivozanib 1tislelizumab 1silmitasertib 1pertuzumab 1peposertib 1pemigatinib 1olutasidenib 1lenvatinib 1inositol trispyrophosphate 1futibatinib 1enasidenib 1devimistat 1derazantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cholangiocarcinoma × Blood Component Removal × Clear all
NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡